Published monthly
by RauCon,
Langer Anger 75,
69115 Heidelberg, Germany
euroPLX 60 Barcelona (Spain) March 7 + 8, 2016 | Barcelona Sea Front Promenade
Business Developer
Vol. 11 # 12 | December | 2015
Featured Vacancies in Business
Development and Licensing
Acadia Pharmaceuticals Inc.:
Director, Business Development,
2015 Ending, So What’s Next Year?
Some call it side effects, others call it fall-out. For business developers, they are opportunities: products, portfolios, drug candidates under development, and assets that need to be divested following a merger.
2015 has seen unprecedented
billion Pfizer/Allergan merger.
Whatever it is, there are side
mergers and acquisitions activi-
The „size imperative“, as some
effects which are interesting for
ties in our industry. Although
observers put it, seems to domi-
the business developer. There
Aesica Pharmaceuticals Ltd.:
the number of deals was prob-
nate. Growth by acquisitions, is it
is no merger that does not pro-
Business Development Manager
ably lower than in 2014, the deal
strategy or just greed? Consider
duce overlapping capabilities,
(2 positions), based in Home
value was much higher, not least
that Pfizer’s tax base may shift to
combined pipeline and portfolio
Office, Germany/UK (http://www.
because mega-mergers are en
Allergan’s home base in Ireland in
redundancies, or antitrust con-
aesica-pharma.co.uk)
vogue, culminating in the $160
order to save taxes…
cerns that stand in the way of
based in San Diego, CA, U.S.A.
(http://www.acadia-pharm.com)
Alkermes Inc.: Manager, Business
Development, based in Waltham,
MA, U.S.A. (http://www.alkermes.
completing a merger. Imminent
Complimentary Advertisement of a euroPLX 60 Barcelona Registrant
Are you looking for competitive generics?
www.almacgroup.com)
Fair-Med offers more than 200 OTC and Rx MA’s with attractive
supply. We offer worldwide license and supply agreements. Fair-Med
also facilitates the technical transfer of production to competitive
suppliers. We are present in most therapeutical areas. Some of our
40 key products are: Amlodipine, Carbidopa/Levodopa, Ibuprofen,
Imatinib, Telmisartan, Temozolomide, Raloxifene and Venlafaxine,
Zoledronic. Please contact [email protected]) …or discuss
this opportunity with us at euroPLX 60 Barcelona!
Amdipharm Mercury Company
Complimentary Advertisement of a euroPLX 60 Barcelona Registrant
com)
Almac Group Ltd.: Business
Development Manager, based
in Souderton, PA, U.S.A. (http://
Limited: Business Development
amcolimited.com)
Antares Pharma, Inc.: Manager of
Business Development/Alliances,
based in Ewing, NJ, U.S.A. (http://
www.antarespharma.com)
Arecor Limited: Business
Development Associate, based
in Cambridge, UK (http://www.
arecor.com)
Aspira Scientific Inc: Business
Development Manager, based in
Milpitas, CA, U.S.A. (http://aspirasci.com)
attention of euroPLX attendees
and a good merger year is always
followed by interesting offers at
euroPLX Conferences.
The volumes to be divested are
considerable. Teva, for example,
is expected to unload about $1
billion worth of assets to address
antitrust concerns over its deal to
buy Allergan Plc’s generic drugs
Analyst - BDA, based in unspecified location, India (http://www.
divestments are what catches the
Calox is Looking for New Business to LA
Calox de Costa Rica offers a widely and strong distributor network in 8
countries, medical reps and more than 80 years of experience in Latin
America Market and we are interested for innovative products, early
and advanced stage development projects (phase 2, 3 and launching),
co-marketing, representation, joint ventures or products with
differential factors to be in license in our territories. Please contact
[email protected] …or discuss this opportunity with us at euroPLX
60 Barcelona!
Complimentary Advertisement of a euroPLX 60 Barcelona Registrant
Inhalation DPI + MDI Products For License
Harvest Moon Pharmaceuticals, USA is developing the folowing
generic inhalation products: fluticasone + salmeterol DPI and MDI;
formoterol + budesonide DPI and MDI; and tiotropium DPI and MDI.
All are available for license in Europe and the USA. Limited territorial
licenses are available. For a commercial quote, please send a country
(countries) forecast (s) and target supply price(s) FOB to: rich.dicicco@
harvestmoonpharma.com …or discuss this opportunity with us at
euroPLX 60 Barcelona!
business, reported Reuters a few
days ago, referring to „people
familiar with the matter“. The
assets to be divested span the
United States, Europe and the
Middle East and some of them
may show up as offers at euroPLX.
These days, euroPLX is finalising a re-launch of its web-site
and online partnering tools, with
easier handling, streamlined
processes, improvements and
innovative features. And it will be
designed for use on smart phones
and tablets, too. The best platform
to divest assets in 2016.
Becton Dickinson & Co.: Sr.
Manager, Strategy & Business
Development, based in San
Diego, CA, U.S.A. (http://www.
bd.com)
Biovest International, Inc.:
Business Development Director,
Europe, based in unspecified
location, anywhere in Europe
(http://www.biovest.com)
Complimentary Advertisement of a euroPLX 60 Barcelona Registrant
New robotic plant for oncology products!
AqVida is a German pharmaceutical company that is specialized
in the development, registration and manufacturing of oncology
FDFs. AqVida is finalizing construction of its new high-tech facility
to manufacture oncology products and ADCs. The facility is a major
innovation for the pharmaceutical industry, using innovative robotic
controlled filling processes for parenteral cytotoxics. Please contact
[email protected] …or discuss this opportunity with us at euroPLX
60 Barcelona!
Complimentary Advertisement of a euroPLX 60 Barcelona Registrant
Boehringer Ingelheim: Senior
Efarmes | Generics Out-license
Strategic Portfolio Manager,
based in Shanghai, China,
People’s Rep. (http://www.
boehringer-ingelheim.com)
Bristol-Myers Squibb Company:
Executive Director, Business
Efarmes develops in-house and looks for companies interested in
licensing + supply agreements. Olmesartan +Amlodipinie +HCTZ is
going to be our next development for the treatment of Hypertension.
We are going to start the BE studies next January 2016 and the
registration dossier will be ready sometime in May-June 2016. Should
you be interested in this triple combination, please feel free to contact
us at [email protected] …or discuss this opportunity with us at
euroPLX 60 Barcelona!
Development, based in New
Brunswick, NJ, U.S.A. (http://www.
bms.com)
Chiesi Farmaceutici SpA: Business
Development & Licensing
Manager, based in Parma, Italy
(http://www.chiesigroup.com)
Collegium Pharmaceutical, Inc.:
Complimentary Advertisement of a euroPLX 60 Barcelona Registrant
We Are Developing - We Are Manufacturing
FERRAZ LYNCE offers a strategic partnership under in-licensing and
out-licensing opportunities. For competitive markets, differentiated
solutions! Our team has added new products with full scientific and
technological support regarding the Respiratory, Circulatory and
CNS areas. We also provide the unique quality and lead time of our
Manufacturing, Packaging and Quality Control services at IBERFAR.
Please contact [email protected] …or discuss this opportunity
with us at euroPLX 60 Barcelona!
Manager, Business Development,
based in Canton, MA, U.S.A.
Sistenic, following an 18 year
career in hedge funds man-
com)
Recent BD&L Manage­
ment Changes
CoNCERT Pharmaceuticals
* Affimed Therapeutics AG:
Inc.: Senior Director, Business
(http://www.collegiumpharma.
Almirall, S.A. acquired 100% of
the Poli Group Holding S.r.l. with
its three operative units Taurus
Pharma GmbH, Polichem S.A. and
Polichem S.r.l. 30 Nov 2015 (www.
almirall.es)
* Co-marketing: APR Applied
Pharma Research S.A. and Eris
Pharmaceuticals (Australia) Pty
Ltd. signed an agreement for the
promotion, distribution and marketing of the Halykoo baby healthcare product line in Australia and
New Zealand. 2 Dec 2015 (www.
apr.ch)
* Acquisition: Aqua Pharma­
ceuticals, LLC acquired the
U.S. rights to two dermatology
products, VELTIN® (clindamycin
phosphate and tretinoin) Gel,
1.2%/0.025% and ALTABAX®
(retapamulin) Ointment, 1%, by
the global pharmaceutical company Almirall, parent company
of Aqua, from GlaxoSmithKline.
Both VELTIN® and ALTABAX® will
be promoted through Aqua in the
United States. 1 Dec 2015 (www.
aquapharm.com)
agement and most recently in
* Acquisition: Astellas Pharma
investment banking, has been
Inc. and Ocata Therapeutics, Inc.
appointed as Head of Corporate
have entered into a definitive
Andrew Curtis, who spent more
Development (Press Release 3 Dec
agreement under which Astellas
Development, based in
than twenty years in the phar-
2015)
will acquire Ocata through Laurel
Lexington, MA, U.S.A. (http://
maceutical and biotechnology
www.concertpharma.com)
sectors, focusing on the licens-
Crown Bioscience: Director
Business Development &
Marketing Japan, based in Tokyo,
Japan (http://www.crownbio.
com)
Dr. Willmar Schwabe Arzneimittel:
Business Development &
Licensing Manager (descr. in
German), based in Karlsruhe,
Germany (http://www.schwabe.
de)
ing, commercial development
and commercialization of new
medicines for rare and neglected
diseases, has been appointed as
Head of Corporate Strategy and
Business Development. (Press
Release 2 Dec 2015)
Company News
*Co-Marketing: Aeterna Zentaris
Inc. finalised a co-marketing
agreement with Armune
BioScience, Inc. that will allow the
Company to promote Armune’s
APIFINY®, the only cancer specific,
* Catalent Pharma Solutions, Inc.:
non-PSA blood test for the detec-
Kevin Hambly, after spending nine
tion of prostate cancer. 1 Dec 2015
years at Seattle Genetics, where he
(www.aezsinc.com)
most recently served as Director
of Business Development and was
Duchesnay Inc.: Senior Manager,
responsible for leading out-licens-
Business Development, based
ing activities, has been appointed
in Blainville QC, Canada (http://
to the position of Vice President,
www.duchesnay.com)
Business Development and
Licensing for Catalent Biologics.
F. Hoffmann - La Roche Ltd.:
Acquisition Inc., a wholly-owned
(Press Release 9 Dec 2015)
Director Business Development,
* Nohla Therapeutics Inc.: Michael
* Investment: Almac Group has
confirmed a £16 million investment to expand its formulation
and analytical development
services to meet ongoing client
demand. 9 Nov 2015 (www.almacgroup.com)
* Acquisition: Laboratorios
subsidiary of Astellas US Holding.
10 Nov 2015 (www.astellas.com)
* Divestment: AstraZeneca has
entered into an agreement
with Perrigo Company plc for
the divestment of US rights to
Entocort® (budesonide), a gastroenterology medicine for patients
with mild to moderate Crohn’s
disease, an area of medicine outside AstraZeneca’s strategic focus.
Under the terms of the agreement, Perrigo will pay AstraZeneca
$380 million. 23 Nov 2015 (www.
astrazeneca.com)
* Investment: BioGaia reporst
that the company made a second
investment of SEK 4 million in
Gothenburg based MetaboGen
and now owns 27% of its share
based in Pleasanton, CA, U.S.A.
capital. 1 Dec 2015 (www.biogaia.
discovery, development and
and Florence, United States. In an
(http://www.roche.com)
com)
commercialisation of innovative
effort to minimise job reductions,
F. Hoffmann - La Roche Ltd.:
* Acquisition: Bristol-Myers
treatments and therapies for rare
the company is actively looking
Global BD and M&A Manager,
Squibb Company has com-
and orphan diseases, appointed
into divestment opportunities for
Roche Diagnostics, based in
pleted the previously announced
Durbin, a specialist provider of
these facilities. 12 Nov 2015 (www.
Basle, Switzerland (http://www.
planned acquisition of Cardioxyl
Managed Access Programs, to
roche.com)
roche.com)
Pharmaceuticals, Inc. The trans-
Fresenius AG: Director New
Therapeutic Area & Business
Development Mature & Emerging
Markets, based in Oberursel,
Germany (http://www.freseniusag.com)
GeneData AG: Business
Development Manager, based in
Basle, Switzerland (http://www.
genedata.com)
action includes full rights to
Cardioxyl’s lead asset CXL-1427, a
novel nitroxyl (HNO) donor (prodrug) in Phase 2 clinical development as an intravenous treatment
for acute decompensated heart
failure (ADHF). 8 Dec 2015 (www.
bms.com)
* Acquisition: BSN medical
announces the acquisition of
Wright Therapy Products, Inc., a
Genentech, Inc.: Manager/
leading manufacturer of compres-
Senior Manager- Research
sion therapy systems, to become a
Tools Technologies, Business
full solution provider of lymphoe-
Development, based in South San
dema care products and expand
Francisco, CA, U.S.A. (http://www.
its portfolio of solutions used to
gene.com)
treat chronic venous insufficiency.
24 Nov 2015 (www.bsnmedical.
Genentech, Inc.: Associate
com)
Director, Oncology Business
manage the warehousing and
supply chain for its products.
Initially this agreement will cover
Emmaus’ pharmaceutical grade
L-glutamine treatment (PGLG),
which is currently under clinical
development having completed
its Phase 3 trial for the management of sickle cell disease (SCD). 3
Dec 2015 (www.emmausmedical.
com)
* Licensing: Grünenthal
announced an exclusive license
agreement with Depomed, Inc. on
the development and commercialisation of Cebranopadol for the
U.S. and Canada. Cebranopadol
is a novel, first in class, potent
analgesic for chronic pain which
has demonstrated its efficacy in
multiple Phase II trials in moderate to severe chronic pain. The
* Divestment: Roche plans to
product is suited for oral, once-
restructure its manufacturing
a- day treatment. Under the terms
network for small molecules to
of the agreement, Depomed, Inc.
address current underutilisation
will take responsibility for further
as a result of its evolving portfolio.
development, marketing and
A new generation of specialised
sales of Cebranopadol in the U.S.
medicines based on small mol-
and Canada, while Grünenthal
ecules requires novel manufac-
will keep the rights for the rest
turing technologies and will be
of the world. Depomed will pay
produced in lower volumes than
Grünenthal an upfront payment
of $25 million in cash, royalties on
Development, Genentech
* Name change: Chugai
traditional medicines. As a result,
Partnering, based in South San
Pharmaceutical Co., Ltd. has
Roche plans to exit four manufac-
net sales of Cebranopadol as well
Francisco, CA, U.S.A. (http://www.
announced that Chugai Pharma
turing sites in Clarecastle, Ireland;
as sales milestones. 17 Nov 2015
gene.com)
Marketing Ltd., a wholly-owned
Leganes, Spain; Segrate, Italy;
(www.grunenthal.com)
subsidiary of Chugai located in
Genentech, Inc.: Associate
London, changed its corporate
Director, Business Develoment
name to Chugai Pharma Europe
(Immunology and Infectious
Ltd. effective November 27. 1 Dec
Disease), based in South San
2015 (www.chugai-pharm.com)
Francisco, CA, U.S.A. (http://www.
gene.com)
Clopidogrel+ASA | Etoricoxib | Pioglitazone+Metformin
has completed the purchase of
Please contact [email protected] …or discuss this opportunity with
us at euroPLX 60 Barcelona!
worldwide exclusive intellectual
Development, based in Boston,
property rights for Fondaparinux
MA, U.S.A. (http://www.genfit.
sodium, its generic anti-coagulant
com)
drug from its Australian partner,
Development Specialst - Chicago,
Alchemia Limited. 18 Nov 2015
(www.drreddys.com)
based in Chicago, IL, U.S.A.
* Acquisition: Eisai Co., Ltd.’s China
(http://www.henryschein.com)
holding company Eisai China
Heumann Pharma: Licensing
Manager, based in Nuremberg,
Germany (http://www.heumann.
de)
Horizon Pharma plc: Director,
Business Development, based in
Deerfield, IL, U.S.A. (http://www.
horizonpharma.com/)
Tecnimede Products for Out Licensing
We are a privately owned group of pharmaceutical companies
dedicated to the development, registration, manufacturing, promotion
and sale of pharmaceutical products for human use. During the 1st
QRT 2016 Tecnimede will have the following dossiers to offer:
* IPR: Dr. Reddy’s Laboratories Ltd.
Genfit Corp.: VP Business
Henry Schein, Inc.: Business
Complimentary Advertisement of a euroPLX 60 Barcelona Registrant
Holdings Ltd. (Location: Suzhou,
Jiangsu Province) has signed an
agreement to purchase 100%
of the shares of Liaoning TianYi
Biological Pharmaceutical Co., Ltd.
27 Nov 2015 (www.eisai.co.jp)
* Distribution: Emmaus Life
Sciences, Inc., a biopharmaceutical company engaged in the
Complimentary Advertisement of a euroPLX 60 Barcelona Registrant
New Patented Formula from Biolab
Biolab has developed a new patented formulation as an innovative
synergy for mitochondrial protection. It ensures the action in various
pathologies, such as: myalgia or weakness in the lower limbs produced
by drugs, diabetes, metabolic syndrome, renal failure, among others.
Please contact: [email protected] …or discuss this
opportunity with us at euroPLX 60 Barcelona!
Complimentary Advertisement of a euroPLX 60 Barcelona Registrant
We Provide Products Ready to Market!
For 20 years, Substipharm has been providing quality products
& services to quality partners! We invest in the development and
manufacturing of our own products to offer you a wide range of
pharmaceutical generic, OTC & niche products. We are by your side
from the registration of the dossier to the supply of the finished
product. Our team would be pleased to provide you with additional
information. Please contact us at [email protected] …or
discuss this opportunity with us at euroPLX 60 Barcelona!
Horizon Pharma plc: Vice
* Distribution: Guerbet completed
company, an exclusive license to
President Business Development,
the acquisition of Mallinckrodt’s
market and sell Innovus Pharma’s
based in Deerfield, IL, U.S.A.
“Contrast Media and Delivery
products: Zestra®, Zestra Glide®,
(http://www.horizonpharma.
Systems” business. The acquisition
EjectDelay®, Sensum+® and
com/)
will bring Guerbet’s employee
Vesele® in Malaysia. Under the
base to 2,500 people and is
agreement, Innovus Pharma will
expected to nearly double our
receive an upfront payment and
turnover to €800M. 27 Nov 2015
is eligible to receive up to $34
(www.guerbet.com)
million dollars in sales milestone
Hovione: Business Development
Manager, based in Lisboa,
Portugal (http://www.hovione.
com)
Impax Laboratories, Inc.:
Associate Director, Business
Development, based in Hayward,
* Licensing: Hanmi
Pharmaceuticals Co. Ltd. has
entered into an exclusive
payments plus an agreed-upon
(www.jnj.com/)
* Acquisition: Lannett Company,
Inc. has completed the acquisition
of Kremers Urban Pharmaceuticals
Inc. (KU), the U.S. specialty generic
pharmaceuticals subsidiary of
global biopharmaceuticals company UCB S.A for $1.23 Billion. 27
Nov 2015 (www.lannett.com)
transfer price. 3 Dec 2015 (www.
* Acquisition: LEO Pharma A/S,
innovuspharma.com/)
and Astellas Pharma Inc. have
entered into an Asset Purchase
license, agreement with Janssen
* Acquisition: Johnson & Johnson
Pharmaceuticals, Inc., for the
completed the acquisition of
development and commerciali-
Novira Therapeutics, Inc., a pri-
Ironwood Pharmaceuticals,
sation of oxyntomodulin-based
vately held, clinical-stage biophar-
Inc.: Senior Manager, Business
therapies including Hanmi’s
maceutical company developing
Development, Search, based in
HM12525A (LAPSGLP/GCG), a
innovative therapies for curative
Cambridge, MA, U.S.A. (http://
novel biologic GLP-1/Glucagon
treatment of chronic hepatitis B
* Divestment: Meda has signed
ironwoodpharma.com)
dual receptor agonist to treat
virus (HBV) infection. 4 Dec 2015
an agreement with The Riverside
CA, U.S.A. (http://www.impaxlabs.
com)
diabetes and obesity, which is
Johnson & Johnson: Director
expected to enter Phase 2 stud-
Business Development, based
ies next year. Janssen will obtain
in Irvine, CA, U.S.A. (http://www.
exclusive worldwide rights, except
jnj.com/)
Korea and China, to develop and
Johnson & Johnson: Business
Development Manager - Janssen
Infectious Disease, based in
Springfield, IL, U.S.A. (http://www.
jnj.com/)
commercialise HM12525A. Hanmi
will receive an upfront payment of
$105 million, and is eligible for up
to $810 million in potential clinical
development, regulatory and sales
milestones. Hanmi Pharmaceutical
Johnson & Johnson: Business
Co., Ltd. also announced a world-
Development Manager Advanced
wide license agreement with
Oncology, based in Moscow,
Sanofi to develop a portfolio of
Russian Federation (http://www.
experimental, long-acting diabe-
jnj.com/)
tes treatments. Hanmi will receive
Medimmune, Inc.: Associate
Director / Director, Partnering &
Strategy, based in Gaithersburg,
MD, U.S.A. (http://www.medimmune.com)
MedMira Laboratories: Business
Development and Sales
Associate, based in Atlanta, GA,
U.S.A. (http://www.medmira.com)
Mega Lifesciences Ltd.: Business
Development Manager (descr. in
Thai), based in Bangna, Bangkok,
Thailand (http://www.megawe-
an upfront payment of EUR 400
million and is eligible for up to
EUR 3.5 billion in development,
as well as double digit royalties
on net sales. Sanofi will obtain an
exclusive worldwide license. 9 and
5 Nov 2015 (www.hanmipharm.
com)
* Divestment: Hikma
Pharmaceuticals PLC has agreed
to sell the manufacturing facilities previously owned by Ben
Venue Laboratories, Inc, based
in Bedford, Ohio, to Xellia
Moderna Therapeutics:
(www.hikma.com)
Development, based in
Cambridge, MA, U.S.A. (http://
will transfer its global dermatology business to LEO Pharma for
€ 675 million. 11 Nov 2015 (www.
leo-pharma.com)
Complimentary Advertisement of a euroPLX 60 Barcelona Registrant
Natrapharm: Unique Chance in the Philippines
As second largest national pharma company (ethical field) in the
Philippines known for its high quality products and competent
field force (500) is looking for a medical food with indications and
clinical trials. Natrapharm´s objective: to market pharmaceutical
products in the Philippine territory through licensing and/or supply
agreements with national and international companies by providing
its partners with comprehensive, integrated service. Please contact
[email protected] …or discuss this opportunity with us at
euroPLX 60 Barcelona!
Complimentary Advertisement of a euroPLX 60 Barcelona Registrant
Day 1 launch opportunities from Alembic Pharma
We are one of the oldest Pharma companies from India with vertical
integration into API, FDF & BE studies. We focus on development and
manufacturing of solid dosages for regulated markets and we are
supplying to USA, 20+ EU countries, Australia etc. We are offering
products for day-1 launch in EU and are looking for partners to
complement our strengths with theirs to penetrate the market. Please
contact [email protected] …or discuss this opportunity with
us at euroPLX 60 Barcelona!
registration and sales milestone,
care.com)
Director/Sr. Director, Business
Agreement under which Astellas
Pharmaceuticals. 25 Nov 2015
* Distribution: Innovus
Pharmaceuticals, Inc. granted
to Bio Task SND BHD, a Malaysia
Complimentary Advertisement of a euroPLX 60 Barcelona Registrant
Vinchem offers NSAID for dysmenorrhea
Vinchem’s first generic product for EU markets is available for
licensing to interested partners; product is Naproxen base 250mg and
500mg tablets (ref. Naprosyn by Roche) available in bulk, bulk blisters
of 10 or finished pack. New dossier with BE study ready for registration
in March 2016. All markets available apart from Italy, Nordic and
MENA regions. Please contact [email protected] …or discuss this
opportunity with us at euroPLX 60 Barcelona!
Complimentary Advertisement of a euroPLX 60 Barcelona Registrant
LAINCO offers quality finished products
LAINCO is a solid Spanish GMP Pharmaceutical and chemical company
with more than 80 years of experience with high quality products.
Specialized in Gastroenterology and Antisepsia, but with other
range of best sellers products, LAINCO offers all its several years
of experience for the companies that are looking for in-licensing
new products on their markets. We are open to discuss all kind of
model business. Please contact [email protected] …or discuss this
opportunity with us at euroPLX 60 Barcelona!
modernatx.com/)
Multipharma SA: Business
Development Manager, based
in Berlin, Germany (http://www.
multipharma.ch)
NextPharma: Business
Complimentary Advertisement of a euroPLX 60 Barcelona Registrant
Grünenthal PRO – Your CMO+
nextpharma.com)
Novartis Pharma AG: Head BD&L,
Asia Cluster, based in Singapore,
Singapore (http://www.novartis.
com)
Novartis Pharma AG: Executive
Director, Business Development &
Complimentary Advertisement of a euroPLX 60 Barcelona Registrant
terms of the transaction were not
Mitelos offers a new concept of oral care
Mitelos has developed, made a patent application and registered
WASHDENT® , a truly ingenious and innovative new concept within oral
care. WASHDENT® is a dietary supplement that allows an “any time, any
place” dental cleaning procedure when toothbrushing is not possible.
Please contact [email protected] …or discuss this opportunity
with us at euroPLX 60 Barcelona!
Complimentary Advertisement of a euroPLX 60 Barcelona Registrant
Lab Vinas seeks distributors in fast growing markets
U.S.A. (http://www.novartis.com)
Lab Vinas (LV ) is a family-owned pharmaceutical company with
international presence, which was founded in Barcelona in 1911.
LV researches, develops, manufactures and markets drugs and
pharmaceutical products (OTC, Medical devices, Cosmetics and Food
supplements) in a wide spectrum of therapeutic areas. LV offers topof-the-line products in dermatology, gynaecology, ophthalmology,
pain and paediatrics to healthcare professionals and consumers. Please
contact [email protected] …or discuss this opportunity with us at
euroPLX 60 Barcelona!
Development & Licensing
Manager, based in Freiburg,
Germany (http://www.novartis.
com)
Novella Clinical: Director, Business
Development, Oncology, based in
Home Office, U.S.A. (http://www.
novellaclinical.com/)
technology company engaged in
the development of therapeutics
Licensing, based in Princeton, NJ,
Novartis Pharma AG: Business
ceuticals Inc., an emerging bio-
We offer our excellence, innovation and service reliability for your
success. As full service CMO we are experienced in manufacture of
APIs, semi-solids, solid and liquid oral dosage forms, in packaging,
storage and distribution of controlled substances.. Please contact
[email protected] …or discuss this opportunity with us at
euroPLX 60 Barcelona!
Development Manager, based in
Göttingen, Germany (http://www.
* Acquisition: Pivot Pharma­
to meet unmet medical needs
in women’s health, has completed the acquisition of IndUS
Pharmaceuticals Inc. Financial
disclosed. 23 Nov 2015 (www.pivotpharma.com/)
* Merger: POZEN Inc. and Tribute
Pharmaceuticals Canada Inc.
confirmed their merger plans
and announced that they have
entered into an amended agreement and plan of merger, which
among other things, moves the
domicile for their proposed parent
company, Aralez Pharmaceuticals
Inc., from Ireland to Canada. 7 Dec
2015 (www.pozen.com)
* Licensing: Quantum Pharma
Plc announced three out-licens-
Company for the sale of Euromed
licensing and investment agree-
ing deals in Germany, though
S.A., a business-to-business manu-
ments valued at up to $50 Mn
Lamda (UK) Limited, Lamda
facturer of herbal extracts and
with Hefei Tianhui Incubator of
Laboratories SA and Lamda
natural active substances located
Technologies Co., Ltd. for exclusive
Pharmaceuticals SA, part of its
in Spain. The total consideration is
rights to market Oramed’s oral
Niche Pharmaceutical division.
Novella Clinical: Director,
EUR 82 million in upfront cash for
insulin capsule, ORMD-0801, in
Under the three licensing, royalty
Business Development- Germany/
the shares of Euromed. The unit
China, Hong Kong and Macau. 30
and supply agreements, Lamda
Eastern Europe, based in unspeci-
generates sales of around EUR 40
Nov 2015 (www.oramed.com)
will out-license two generic plus
fied location, Germany (http://
million and an EBITDA margin of
www.novellaclinical.com/)
around 20% on an annual basis. 1
Novozymes A/S: Project Manager,
Dec 2015 (www.meda.se)
* Acquisition: Perrigo Company
plc will acquire Entocort® (budesonide) capsules as well as the
and one generic dossiers which
Lamda developed. The total fixed
licensing fee from these three
agreements will be, in aggregate,
Business Development, based
* Licensing: Moberg Pharma AB
authorised generic capsules
in Beijing, China, People’s Rep.
and Meda have agreed to amend
marketed by Par Pharmaceuticals
(http://www.novozymes.com)
their existing license and distribu-
within the U.S. from AstraZeneca
tion agreement so Moberg regains
plc for $380 million. 23 Nov 2015
* Acquisition: Sucampo
rights to the nail product in cer-
(www.perrigo.com)
Pharmaceuticals, Inc., a global
Oncodesign S.A.: Business
Development Manager, based
in Dijon, France (http://www.
oncodesign.com)
tain EU markets. This includes UK,
Poland, the Chech Republic and
the Baltic countries. The two com-
Pacira Pharmaceuticals, Inc.:
panies maintain their partnership
Executive Director, Business
in the remaining thirteen markets
Development, based in
where the product has been
Parsippany, NJ, U.S.A. (http://
launched under the brand names
pacira.com)
Naloc and Nalox. 10 Nov 2015
(www.mobergderma.se)
Panacea Biotec Ltd.: Sr. Manager/
* Acquisition: Pfizer Inc’s and
Allergan plc’s boards of directors
have unanimously approved, and
the companies have entered into,
a definitive merger agreement
under which Pfizer will combine
with Allergan in a stock transaction currently valued at $363.63
€375,000. 30 Nov2015 (www.
quantumpharmagroup.com)
biopharmaceutical company,
announced the completion of its
acquisition of R-Tech Ueno and
all remaining outstanding shares.
Sucampo acquired R-Tech Ueno
for 32.8 billion Japanese Yen (JPY),
or approximately $275 million. 7
Dec 2015 (www.sucampo.com)
per Allergan share, for a total
* Acquisition: Tarrex Biopharma
AGM – Business Development –
* Licensing: Oramed Pharma­
enterprise value of approximately
Ltd has acquired a 33% stake in
Contract Research (CRO), based
ceuticals Inc., a clinical-stage
$160 billion, based on the closing
Aranda Pharma Ltd of Finland. The
in New Delhi, India (http://www.
pharmaceutical company focused
price of Pfizer common stock of
two small biopharma companies
panaceabiotec.com)
on the development of oral drug
$32.18 on November 20, 2015. 23
will be co-developing Aranda’s
delivery systems, announced
Nov 2015 (www.pfizer.com)
androgen receptor antagonist
Piramal Healthcare: Chief
today it has signed definitive
for the treatment of Castration
Manager – Business
Resistant Prostate Cancer. 3 Nov
ics, supplements, and medical
Development, based in Mumbai,
2015 (www.tarrexbio.com)
devices.
India (http://www.piramal.com)
* Investment: Torrent Pharma­
Chemineau Labs (www.chem-
PPD, Inc.: Executive Director,
ceuticals Ltd has commenced
ineau.com) is a CDMO which
Business Development
commercial operations at its
is located in Vouvray, France,
(Strategic Partnerships), based
new plant in Dahej. This is the
specialised in liquid and pasty
in Morrisville, NC, U.S.A. (http://
Company’s 5th formulation Plant
forms manufacturing and filling:
www.ppdi.com)
and the 2nd API Plant. The facility
contract development, scale-up
is being set up in a two phases.
transfer, purchasing, production,
The total investment made in the
regulatory affairs, etc.
Purdue Pharma L.P.: Senior
Manager - Business Development
Liaison, based in Stamford, CT,,
U.S.A. (http://www.pharma.com)
Remedica Ltd: Business
Development Officer, based in
Limassol, Cyprus (http://www.
remedica.eu)
first phase of the plant is over Rs.
650 crores (6.5 bn). 5 Nov 2015
(www.torrentpharma.com)
(www.gunainternational.com)
produces and distributes low
* Divestiture: UCB completed its
dose medicines, medical devices,
previously announced transaction
food supplements and cosmetics.
providing for the sale of UCB’s
Guna’s products are distributed in
U.S. specialty generics subsidiary,
over 40 countries.
Rigel Pharmaceuticals Inc.: Dir.,
Kremers Urban Pharmaceuticals
Business Development/Market
Inc., to Lannett Company, Inc.
Strategy, based in South San
Kremers has been sold by UCB to
Francisco, CA, U.S.A. (http://www.
Lannett for total consideration of
rigel.com)
approximately US$ 1.23 billion,
consisting of cash consideration of
Sanofi US: Area Business
US$ 1.03 billion (subject to certain
Development Manager, based in
adjustments) and US$ 200 million
South-West, UK, UK (http://www.
senior unsecured notes issued
sanofi.us)
to UCB by Lannett. 25 Nov 2015
Takeda Pharmaceuticals
Based in Milan, Italy, Guna Spa
(www.ucb.com)
Laboratorios Vinas (www.vinas.es)
is a family-owned pharmaceutical
company with international presence. The company is based in
Barcelona, Spain, and researches,
develops, manufactures and markets drugs and pharmaceutical
products (OTC, medical devices,
cosmetics, food supplements) in
a wide spectrum of therapeutic
areas with an emphasis on der-
North America, Inc.: Business
* Acquisition: Xellia Pharma­
matology, dermo-cosmetics and
Development Manager - Mexico,
ceuticals has acquired manufac-
gynaecology.
based in Mexico, Mexico (http://
turing facilities in Bedford, Ohio,
www.takeda.us/)
from a wholly owned subsidiary
Takeda Pharmaceuticals North
America, Inc.: Director, PV
Business Development & Alliance
Management, based in Boston,
MA, U.S.A. (http://www.takeda.
us/)
of Hikma Pharmaceuticals. 25 Nov
2015 (www.xellia.com)
euroPLX Newcomers at
euroPLX 60 Barcelona
Here is part 1 of companies
VirtualScopics, Inc.: Director of
which registered for euroPLX 60
Business Development, based in
Barcelona (March 7 + 8, 2016) and
Rochester, NY, U.S.A. (http://www.
are newcomers to euroPLX, i.e.
virtualscopics.com)
they have never had a delegate at
a euroPLX Conference before:
WuXi PharmaTech Co Ltd:
Director of Business Development
Headquartered in Tokyo, CBC
for Analytical Development &
Corporation Limited (www.glob-
Formulation Development, based
al-cbc.com) is a manufacturer, a
in unspecified location, U.S.A.
trading company, and a full range
(http://www.wuxiapptec.com)
supplier of chemicals, synthetic
resins, and pharmaceuticals to
electronics components & devices,
security devices, and more. For
More BD&L vacancies in pharma
and biotech are regularly listed
on www.raucon.com
Responsible Editor: Dr. Norbert Rau
the pharmaceutical industry, CBC
offers API/Intermediates, excipients, peptide nucleic acid, cosmet-
Working from our state-of-theart facilities across the United
States and Europe, Sharp Clinical
Services (www.sharpservices.com)
provide unique and often complex commercial and clinical packaging solutions to the pharmaceutical and biotechnology industry:
cost-effective blister packaging,
bottling, pouches and stick packs,
compliance packaging, formulation and manufacturing services,
label design and printing.